Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans

This study has been completed.
Sponsor:
Collaborators:
German Research Foundation
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Joerg Schirra, Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:
NCT00393445
First received: October 26, 2006
Last updated: October 2, 2011
Last verified: October 2011

October 26, 2006
October 2, 2011
November 2006
Not Provided
To assess the effect of increasing doses of exendin(9-39) on first and second phase insulin secretion stimulated by intravenous GLP-1 during hyperglycemia [ Time Frame: within the actual study period ]
To assess the effect of increasing doses of exendin(9-39) on plasma insulin levels stimulated by intravenous GLP-1 during hyperglycemia.
Complete list of historical versions of study NCT00393445 on ClinicalTrials.gov Archive Site
To assess the effect of increasing doses of exendin(9-39) on plasma glucagon levels decreased by intravenous GLP-1 during hyperglycemia [ Time Frame: within the actual study period ]
To assess the effect of increasing doses of exendin(9-39) on plasma glucagon levels decreased by intravenous GLP-1 during hyperglycemia.
Not Provided
Not Provided
 
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
Effect of GLP-1 on Glucose Metabolism in Healthy Subjects and Patients With T2DM. Part 1: A Pilot Study to Assess the Efficacy of Exendin(9-39)Amide as a GLP-1 Receptor Antagonist in Healthy Subjects

The purpose of this study is to determine the dose of the GLP-1 receptor antagonist exendin(9-39) which blocks the insulinotropic action of synthetic GLP-1 by at least 95%.

Following a meal, gut-produced incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the circulation. GLP-1 and GIP, the two dominant incretin hormones, are part of a natural endogenous system involved in maintaining glucose homeostasis. In the presence of normal or elevated, but not low, glucose concentration, both GLP-1 and GIP increase insulin secretion from pancreatic islet beta-cells (β-cells). GLP-1 also lowers glucagon secretion from pancreatic alpha-cells and delays nutrient delivery from the stomach by inhibiting gastric emptying. This rise in insulin concentration enhances glucose clearance in peripheral tissues such as muscle, and the lower glucagon concentration combined with the rise in insulin reduces hepatic glucose production. By enhancing glucose clearance and lowering hepatic glucose production, the post-meal glucose excursion is reduced.

However, the role that each incretin has in glucoregulation is not fully understood. Use of a GLP-1 antagonist, exendin (9-39)NH2, will allow for the assessment of non-GLP-1 incretin's role in glucoregulation. Therefore, it is of great interest to examine the role that specific incretins have in glucoregulation in patients with T2DM.

Exendin(9-39) has been shown a specific and reversible antagonist at the human GLP-1 receptor in vivo. In initial validation studies intravenous exendin(9-39) dose-dependently reduced the insulinotropic action of intravenous GLP-1. The maximal dose of 300 pmol/kg/min used in these studies was sufficient to reduce GLP-1 stimulated insulin plasma levels by about 83%. However, to quantify the contribution of incretin hormones to the incretin effect as stated above a nearly complete inhibition of the GLP-1 action is necessary.

Therefore the purpose of this pilot study is to characterize the dose-response characteristics of exendin(9-39) more completely and to find a dosage which inhibits the insulinotropic action of GLP-1 by at least 95%.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Diagnostic
Hyperglycemia
  • Drug: GLP-1 control
    intravenous infusion of GLP-1
    Other Name: GLP-1(7-36)amide
  • Drug: GLP-1 and Exendin(9-39) 300
    intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
  • Drug: saline control
    intravenous infusion of saline
  • Drug: GLP-1 and Exendin(9-39) 600
    intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
  • Drug: GLP-1 and Exendin(9-39) 900
    intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
  • Drug: GLP-1 and Exendin(9-39) 1200
    intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Experimental: Intravenous infusion
intravenous infusion of test substances
Interventions:
  • Drug: GLP-1 control
  • Drug: GLP-1 and Exendin(9-39) 300
  • Drug: saline control
  • Drug: GLP-1 and Exendin(9-39) 600
  • Drug: GLP-1 and Exendin(9-39) 900
  • Drug: GLP-1 and Exendin(9-39) 1200

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
May 2007
Not Provided

Inclusion Criteria:

  • Male or female (postmenopausal, surgically sterile or using double-barrier method of contraception) healthy volunteers
  • Age 18-65 years
  • Hemoglobin A1c (HbA1c) < 6%
  • Body mass index (BMI) < 30 kg/m2
  • Must have a fasting blood glucose below 100 mg/dl at screening and on all study days
  • Able to provide written informed consent prior to study participation
  • Able to communicate well with the investigator and comply with the requirements of the study

Exclusion Criteria:

  • Diabetes mellitus
  • Fasting triglycerides > 5.1 mmol/L (> 450 mg/dL) within the past 4 weeks.
  • Treatment with systemic steroids and thyroid hormone
  • Patients with any history of gastrointestinal surgery, e.g. partial bowel resections, partial gastric resections, etc.
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
  • Significant illness within the two weeks prior to dosing.
  • Past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history of a prolonged QT-interval syndrome.
  • History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study. The investigator should be guided by evidence of any of the following:

    • history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding
    • history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
    • history or clinical evidence of pancreatic injury or pancreatitis
    • history or presence of impaired renal function as indicated by abnormal creatinine or urea values or abnormal urinary constituents (e.g., albuminuria)
    • evidence of urinary obstruction or difficulty in voiding at screening
  • Polymorphonuclears < 1500/µL at inclusion or platelet count < 100,000/μL at screening and baseline.
  • Evidence of liver disease as indicated by abnormal liver function tests such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin.
  • History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00393445
DOF-Ex, DFG Schi 527/1-2
No
Joerg Schirra, Ludwig-Maximilians - University of Munich
Ludwig-Maximilians - University of Munich
  • German Research Foundation
  • Merck Sharp & Dohme Corp.
Study Chair: Joerg Schirra, MD Clinical Research Unit (CRU), Department of Internal Medicine II-Grosshadern, Ludwig-Maximilans-University of Munich
Ludwig-Maximilians - University of Munich
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP